GMP facility supports micronized production

Stockholm-based XSpray Microparticles has launched a GMP production capability to produce drug particles and powders for use in clinical studies, which augments the company's particle development and characterization services.

The fluid technology company worked with Swedish CRO Galenica to develop a GMP facility in Malmo. Galencia will conduct the manufacturing operations.

XSpray says in an announcement that the facility allows it to satisfy customer needs for GMP-quality volumes of its micronized drug particles and powders, used in inhaled compounds, sparingly soluble compounds and biopharmaceuticals. The facility proves that the micronization technique, based on supercritical fluid technology, can be scaled-up, a step towards full pharma manufacturing.

The facility complies with both EU and U.S. regulatory standards.

- here's the release

Suggested Articles

The partnership aims to make the production of vaccines that use adenovirus as vectors more cost-effective and contamination-free.

The FDA hit New Jersey-based CMO Tris Pharma with a warning letter, citing significant violations.

Celltrion remains optimistic it will get U.S. approval for its two biosimilar drugs, Rituxan and Herceptin, by the end of the year.